TScan Therapeutics, Inc. (TCRX) Investor Relations Documents

TScan Therapeutics, Inc. (TCRX) investor relations documents from the company's IR site: 13 presentations, 3 press releases; latest deck 2026-05-20. Read in-app with summaries. First-party data.

Novel CD45-targeted TCR-T cell therapies designed to eliminate residual disease and prevent relapse following hematopoie: TScan Therapeutics corporate profile detailing its development of CD45-targeted TCR-T cell therapies to eliminate residual disease and prevent relapse after hematopoietic cell

Investor relations documents — source: company IR site

Published	Type	Document
2026-05-20	Presentation	Novel CD45-targeted TCR-T cell therapies designed to eliminate residual disease and prevent relapse following hematopoie
2026-03-19	Presentation	Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to T
2026-03-19	Presentation	Product Characteristics and Clinical Trial Design for T-Plex, a Multiplexed, Enhanced T cell Receptor-Engineered T cell
2026-03-19	Presentation	Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Hetero
2026-03-19	Presentation	Phase 1 Trial of TSC-100 and TSC-101, Engineered T-Cell Therapies Targeting Minor Histocompatibility Antigens to Elimina
2026-03-19	Presentation	Phase 1 trial of TSC-100 and TSC-101, Engineered T-Cell Therapies Targeting Minor Histocompatibility Antigens to Elimina
2026-03-19	Presentation	Non-Clinical Development of T-Plex Component TSC-201-B0702: a TCR-T Cell Therapy Directed to a Novel HLA-B*07:02-Restric
2026-03-19	Presentation	Multiplexed TCR-T Therapy: A Strategy to Enhance the Efficacy of Engineered Adoptive Cell Therapy.
2026-03-19	Presentation	Initial Results of a Phase 1 trial of TSC-100 and TSC-101, Engineered T Cell Therapies that Target Minor Histocompatibil
2026-03-19	Presentation	Discovery of TSC-200-A02: A Natural HPV16 E7-specific TCR-T Cell Therapy Candidate for the Treatment of HPV-positive Sol
2026-03-19	Presentation	A First in Class Natural HA-2 Specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy.
2026-03-19	Press release	TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-free Survival in Patients wit
2026-03-19	Presentation	Overcoming tumor heterogeneity – Clinical trial assays to prospectively assign patients customized multiplexed TCR-T cel
2026-03-19	Presentation	Nonclinical development of T-Plex component TSC-204-A0101: a natural TCR-T cell therapy for the treatment of MAGE-A1- an
2025-12-06	Press release	TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of H
2025-12-03	Press release	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Marke

TCRX overview · TCRX earnings · TCRX financials · TCRX KPIs · TCRX ownership · TCRX peers · TCRX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.